In short
This article discusses a clinical trial investigating the use of Prednisone Acetate tablets in combination with other drugs for treating metastatic castration-resistant prostate cancer. The study aims to evaluate the safety and effectiveness of this combination therapy in patients with advanced prostate cancer.
At a glance
- Study Type
- Phase Ib/II clinical trial
- Condition
- Metastatic Castration-Resistant Prostate Cancer
- Intervention
- TQB3823 tablets + Abiraterone acetate tablets + Prednisone acetate tablets
- Primary Outcomes
- Dose-limiting toxicity, Recommended phase II dose, Radiographic progression-free survival
- Secondary Outcomes
- PSA reduction, Overall response rate, Overall survival, Clinical benefit rate, Duration of response
- Safety Measures
- Adverse event rates (up to 24 months)
- Treatment Cycle
- 28 days
What is Prednisone Acetate?
Prednisone Acetate is a medication that belongs to a class of drugs called corticosteroids. It is a synthetic version of hormones naturally produced by the adrenal glands. Prednisone Acetate is used to treat various medical conditions due to its anti-inflammatory and immunosuppressive properties.
Medical Conditions Treated
In the context of the clinical trials discussed, Prednisone Acetate is being used in combination with other medications to treat metastatic castration-resistant prostate cancer (mCRPC). This is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to treatments that lower testosterone levels.
Usage in Clinical Trials
Prednisone Acetate is being used in two Phase 3 clinical trials for patients with mCRPC:
- A trial comparing MK-5684 with abiraterone acetate or enzalutamide in patients who have previously received hormonal therapy and chemotherapy.
- A trial comparing MK-5684 with abiraterone acetate or enzalutamide in patients whose cancer progressed after treatment with one next-generation hormonal agent (NHA).
In these trials, Prednisone Acetate is used as a supportive medication, likely to help manage side effects or enhance the effectiveness of other treatments.
Dosage and Administration
According to the clinical trial information, Prednisone Acetate is administered as follows:
- Form: Tablet
- Route: Oral use (taken by mouth)
- Maximum daily dose: 10 mg
- Maximum total dose: 12,810 mg
- Maximum treatment period: 42 months (3.5 years)
It's important to note that these dosages are specific to the clinical trials and may not reflect standard treatment protocols. Always follow your doctor's instructions regarding dosage and administration.
Potential Side Effects
While specific side effects are not mentioned in the trial data, corticosteroids like Prednisone Acetate can cause various side effects, including:
- Increased appetite and weight gain
- Mood changes
- Increased blood sugar levels
- Fluid retention
- Weakened immune system
- Osteoporosis (with long-term use)
Your healthcare provider will monitor you for these and other potential side effects during treatment.
Precautions and Contraindications
Based on the clinical trial exclusion criteria, patients with the following conditions may not be suitable for treatment with Prednisone Acetate:
- History of pituitary dysfunction
- Poorly controlled diabetes mellitus
- Clinically significant abnormal serum potassium or sodium levels
- Active infections requiring systemic therapy
- Certain cardiovascular conditions
Interactions with Other Medications
The clinical trial data suggests potential interactions with:
- Strong CYP3A4 inducers and P-glycoprotein (P-gp) inhibitors
- Cytochrome P450 (CYP450)-inducing antiepileptic drugs
- Certain hormonal therapies and chemotherapy drugs
Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.